M Toi

Summary

Country: Japan

Publications

  1. ncbi Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer
    Seigo Nakamura
    Department of Breast Surgical Oncology, St Luke s International Hospital, Chuo Ku, Tokyo, Japan
    Breast Cancer 17:199-204. 2010
  2. ncbi Decision tree and paradigms of primary breast cancer: changes elicited by preoperative therapy
    Masakazu Toi
    Breast Oncology Unit, Tokyo Metropolitan Komagome Hospital, Tokyo Metropolitan Medical Center for Cancer and Infectious Diseases, 3 18 22 Honkomagome, Bunkyo ku, 113 8677 Tokyo, Japan
    Med Sci Monit 9:RA90-5. 2003
  3. ncbi Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival
    Masakazu Toi
    Department of Surgery Breast Surgery, Graduate School of Faculty of Medicine, Kyoto University, 54 Shogoin Kawara cho, Sakyo ku, Kyoto 606 8507, Japan
    Breast Cancer Res Treat 110:531-9. 2008
  4. ncbi Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications
    M Toi
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Japan
    Lancet Oncol 2:667-73. 2001
  5. ncbi Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer
    Masakazu Toi
    Breast Unit, Tokyo Metropolitan Komagome Hospital, Bunkyo ku, Tokyo, Japan
    Int J Cancer 98:14-8. 2002
  6. ncbi Current status of antibody therapy for breast cancer
    Masakazu Toi
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, 3 18 22 Honkomagome, Bunkyo ku, Tokyo 113 8677, Japan
    Breast Cancer 11:10-4. 2004
  7. ncbi Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer
    M Toi
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, 3 18 22, Honkomagome, Bunkyo ku, Tokyo 113 8677, Japan
    Br J Cancer 90:2338-43. 2004
  8. ncbi Aromatase and aromatase inhibitors
    M Toi
    Tokyo Metropolitan Komagome Hospital, 3 18 22, Honkomagome, Bunkyo ku, Tokyo 113, Japan
    Breast Cancer 8:329-32. 2001
  9. ncbi Translational research in breast cancer
    Masakazu Toi
    Department of Clinical Trials and Research, Metropolitan Komagome Hospital, Tokyo Metropolitan Cancer and Infectious Disease Centre, 3 18 22, Honkomagome Bunkyo ku, Tokyo, 113 8677, Japan
    Breast Cancer 12:86-90. 2005
  10. ncbi Vascular endothelial growth factor and its relationships with endogenous inhibitors in a breast cancer microenvironment manipulated by hormonal therapy: a hypothetical consideration
    M Toi
    Department of Clinical Trials and Research, Metropolitan Komagome Hospital, Tokyo Metropolitan Cancer and Infectious Disease Center, Japan
    Biomed Pharmacother 59:S344-7. 2005

Collaborators

Detail Information

Publications109 found, 100 shown here

  1. ncbi Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer
    Seigo Nakamura
    Department of Breast Surgical Oncology, St Luke s International Hospital, Chuo Ku, Tokyo, Japan
    Breast Cancer 17:199-204. 2010
    ..In this prospective study, we evaluated CTCs in predicting treatment efficacy and overall survival (OS) using the CellSearch System (Veridex, LLC, Raritan, NJ)...
  2. ncbi Decision tree and paradigms of primary breast cancer: changes elicited by preoperative therapy
    Masakazu Toi
    Breast Oncology Unit, Tokyo Metropolitan Komagome Hospital, Tokyo Metropolitan Medical Center for Cancer and Infectious Diseases, 3 18 22 Honkomagome, Bunkyo ku, 113 8677 Tokyo, Japan
    Med Sci Monit 9:RA90-5. 2003
    ..For instance, if SNB is conducted before the treatment, the over-treatment issue can be eliminated. In this article, we will discuss the changes in decision-tree and paradigms for primary..
  3. ncbi Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival
    Masakazu Toi
    Department of Surgery Breast Surgery, Graduate School of Faculty of Medicine, Kyoto University, 54 Shogoin Kawara cho, Sakyo ku, Kyoto 606 8507, Japan
    Breast Cancer Res Treat 110:531-9. 2008
    ..QpCR following preoperative chemotherapy predicts favorable DFS. HER2 overexpression and clinical response to FEC predict QpCR...
  4. ncbi Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications
    M Toi
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Japan
    Lancet Oncol 2:667-73. 2001
    ..This review considers the clinical implications of VEGF, particularly its prognostic, predictive, and therapeutic value...
  5. ncbi Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer
    Masakazu Toi
    Breast Unit, Tokyo Metropolitan Komagome Hospital, Bunkyo ku, Tokyo, Japan
    Int J Cancer 98:14-8. 2002
    ..In conclusion, sVEGFR1, an intrinsic inhibitor of VEGF, frequently co-expressed with VEGF in primary breast cancer tissues. The intratumoral balance between sVEGFR1 and VEGF levels might be crucial for the progression of breast cancer...
  6. ncbi Current status of antibody therapy for breast cancer
    Masakazu Toi
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, 3 18 22 Honkomagome, Bunkyo ku, Tokyo 113 8677, Japan
    Breast Cancer 11:10-4. 2004
    ..We reviewed recent advances in trastuzumab treatment and discuss the future of antibody therapy for breast cancer...
  7. ncbi Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer
    M Toi
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, 3 18 22, Honkomagome, Bunkyo ku, Tokyo 113 8677, Japan
    Br J Cancer 90:2338-43. 2004
    ..Thymidine phosphorylase upregulation by several anticancer drugs implies the importance of individualised strategies for sensitisation of tumour tissues to 5-FU and its derivatives...
  8. ncbi Aromatase and aromatase inhibitors
    M Toi
    Tokyo Metropolitan Komagome Hospital, 3 18 22, Honkomagome, Bunkyo ku, Tokyo 113, Japan
    Breast Cancer 8:329-32. 2001
    ....
  9. ncbi Translational research in breast cancer
    Masakazu Toi
    Department of Clinical Trials and Research, Metropolitan Komagome Hospital, Tokyo Metropolitan Cancer and Infectious Disease Centre, 3 18 22, Honkomagome Bunkyo ku, Tokyo, 113 8677, Japan
    Breast Cancer 12:86-90. 2005
    ..In this regard, TR can accelerate the development of new methodologies and increase trial efficiency. In this review, we describe the importance of TR, particularly that related to novel therapeutics...
  10. ncbi Vascular endothelial growth factor and its relationships with endogenous inhibitors in a breast cancer microenvironment manipulated by hormonal therapy: a hypothetical consideration
    M Toi
    Department of Clinical Trials and Research, Metropolitan Komagome Hospital, Tokyo Metropolitan Cancer and Infectious Disease Center, Japan
    Biomed Pharmacother 59:S344-7. 2005
  11. ncbi Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment
    Masakazu Toi
    Department of Clinical Trials and Research, Tokyo Metropolitan Cancer and Infectious Disease Centre, Komagome Hospital, Tokyo, Japan
    Lancet Oncol 6:158-66. 2005
    ..This new idea, the improvement of TP-inducible therapy with TP-targeting therapy, should be further investigated for early disease states, and inhibitors of TP warrant extensive investigation...
  12. ncbi Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes
    Masakazu Toi
    Department of Clinical Trials and Research, Tokyo Metropolitan Komagome Hospital, 3 18 22 Honkomagome, Bunkyo ku, Tokyo, 113 8687 Japan
    Jpn J Clin Oncol 35:310-5. 2005
    ....
  13. ncbi Trastuzumab: updates and future issues
    Masakazu Toi
    Department of Clinical Trial and Research, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Honkomagome 3 18 22, Bunkyo ku, Tokyo, 113 8677, Japan
    Cancer Chemother Pharmacol 56:94-9. 2005
    ..It might also be important to investigate, with greater depth, the interaction between the Her-axis and the hormone-axis. This short review describes and discusses these topics...
  14. ncbi Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer
    M Toi
    Department of Surgery, Breast Oncology, Tokyo Metropolitan Komagome Hospital, Japan
    Clin Cancer Res 5:1131-7. 1999
    ..TP might be such a marker, which would be useful for identifying the character of TAMs, particularly the protumor phenotype...
  15. ncbi Circulating levels of endostatin in cancer patients
    K Kuroi
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Bunkyo ku, Tokyo 113 8677, Japan
    Oncol Rep 8:405-9. 2001
    ..05, log-rank test). Our data demonstrate that PESLs are detectable in healthy controls, and that cancer patients have elevated PESLs. A larger study is warranted to clarify the clinical significance of circulating endostatin...
  16. ncbi Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer
    T Tominaga
    Breast Cancer Center, Toyosu Hospital, Showa University School of Medicine, Tokyo, Japan
    Ann Oncol 14:62-70. 2003
    ....
  17. ncbi Circulating angiogenesis regulators in cancer patients
    K Kuroi
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Japan
    Int J Biol Markers 16:5-26. 2001
    ....
  18. ncbi Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique
    M Takada
    Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Kawaracho, Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Breast Cancer Res Treat 134:661-70. 2012
    ..Our model based on clinicopathological variables showed high predictive ability for pCR. This model might improve the prediction of the response to NAC in primary breast cancer patients...
  19. ncbi Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer
    S Ohnoa
    Japan Breast Cancer Research Group, c o Komagome Hospital, Bunkyo ku, Tokyo, Japan
    Biomed Pharmacother 59:S323-4. 2005
    ..The pathologic response rate was 17%. In this ongoing trial, FEC followed by DOC was active and well tolerated...
  20. ncbi Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer
    H Bando
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo Metropolitan Cancer and Infectious Disease Center, 3 18 22, Honkomagome Bunkyo ku, Tokyo 113 8677, Japan
    Br J Cancer 92:553-61. 2005
    ..In conclusion, the intratumoral sVEGFR-1 level, VEGF level and the ratio of sVEGFR-1 to total VEGF are potent prognostic indicators of primary breast cancer, and might be relevant to ER status...
  21. ncbi Clinical significance of plasma nucleosome levels in cancer patients
    K Kuroi
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, 3 18 22 Honkomagome, Bunkyo ku, Tokyo 113 8677, Japan
    Int J Oncol 19:143-8. 2001
    ..Thus, increased PNLs were found in cancer patients, and PNLs seem to be a sensitive marker of cell death that could be predictive of both leukopenia and response to chemotherapy...
  22. ncbi [Current status and the perspective of treatment strategy for the patients with advanced or recurrent breast cancer]
    Dai Kitagawa
    Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital
    Nippon Rinsho 65:396-401. 2007
  23. ncbi [Herceptin (trastuzumab)]
    Hiroyasu Yamashiro
    Dept of Surgery, Graduate School of Medicine, Kyoto University, Japan
    Gan To Kagaku Ryoho 34:1173-6. 2007
    ..Results of large-scale randomized trials and preclinical study might answer these questions. This review summarizes current knowledge about trastuzumab treatment...
  24. ncbi [Primary systemic chemotherapy for breast cancer]
    Masahiro Takada
    Dept of Breast Surgery, Graduate School of Medicine, Kyoto University Hospital, Kyoto University, Japan
    Gan To Kagaku Ryoho 34:1730-4. 2007
    ..We reviewed recent advances in neoadjuvant chemotherapy for breast cancer...
  25. ncbi Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies
    M Toi
    Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawaracho, Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Br J Cancer 101:1676-82. 2009
    ..Efficacy and safety of lapatinib monotherapy was evaluated in Japanese breast cancer patients after trastuzumab-based therapies...
  26. ncbi Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma
    H Saji
    Department of Surgery, Breast Oncology Unit, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
    Cancer 92:1085-91. 2001
    ..CONCLUSIONS: The results of this study suggest that MCP-1 may play key roles in macrophage recruitment, in the expression of angiogenic factors, and in the activation of matrix metalloproteinases in patients with breast carcinoma...
  27. ncbi Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration
    T Ueno
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Japan
    Br J Cancer 83:164-70. 2000
    ....
  28. ncbi Improving the efficacy of trastuzumab in breast cancer
    Eiji Suzuki
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo 113 8677, Japan
    Cancer Sci 98:767-71. 2007
    ..Here, we discuss both clinical and preclinical data regarding these issues...
  29. ncbi Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread
    Hiroko Bando
    Breast Unit, Tokyo Metropolitan Komagome Hospital, Bunkyo ku, Tokyo 113 0021, Japan
    Jpn J Cancer Res 93:389-96. 2002
    ..Thus, MIF seems to play a role in tumor-stroma interactions of primary breast cancers, particularly those with a phenotype of node-negative or minimal nodal spread...
  30. ncbi [Controversies in endocrine therapy for breast cancer]
    Masayo Kawakami
    Department of Surgery and Breast Oncology, Tokyo Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan
    Gan To Kagaku Ryoho 31:181-7. 2004
    ..Further research concomitant with clinical trials may lead to a more reliable endocrine therapy modality in the treatment of breast cancer...
  31. ncbi Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery
    Takeshi Tominaga
    Breast Cancer Center, Toyosu Hospital, Showa University School of Medicine, Tokyo, Japan
    J Clin Oncol 21:991-8. 2003
    ....
  32. ncbi Application of a continual reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer
    Satoshi Morita
    Department of Epidemiological and Clinical Research Information Management, Kyoto University, Kyoto, Japan
    Jpn J Clin Oncol 34:104-6. 2004
    ..We conducted a survey of the clinical oncologists participating in this trial to determine the dose escalation/de-escalation rule, including a prior distribution for model parameters used in the CRM...
  33. ncbi Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy
    Masakazu Toi
    Department of Surgery Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto 606 8507, Japan
    Int J Oncol 31:899-906. 2007
    ..After 2 years, the RPV of TS decreased with time, suggesting that 2 years of treatment with oral fluorouracil derivatives may be inadequate. Further studies are required to investigate this possibility...
  34. ncbi Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer
    Masakazu Toi
    Department of Surgery and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawara cho, Sakyo ku, Kyoto 606 8507, Japan
    Breast Cancer 16:207-18. 2009
    ..e., after some period of prior tamoxifen) have been proposed. The benefits and drawbacks of these approaches to AI treatment, particularly with respect to reducing early DM recurrences, are reviewed...
  35. ncbi Establishment of bone marrow-derived endothelial cell lines from ts-SV40 T-antigen gene transgenic rats
    K Hattori
    Department of Pharmaceutics, Kyoritsu College of Pharmacy, Tokyo, Japan
    Pharm Res 18:9-15. 2001
    ..All markers were expressed strongly in clone 3. CONCLUSIONS: These data confirm that the above three TR-BME cells are novel ECs derived from bone marrow progenitors...
  36. ncbi Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer
    Masakazu Toi
    Faculty of Medicine, Kyoto University, Kyoto, Japan
    BMC Cancer 10:56. 2010
    ..Here we investigate the relationship between HER2 expression or HER2 homodimers and OS in a clinic-based population of patients with MBC selected primarily by IHC...
  37. ncbi Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients
    Kazumi Horiguchi
    Department of Human Pathology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan
    J Med Dent Sci 57:165-75. 2010
    ..We investigated the significance of CD24 and CD44 expression for predicting responses to chemotherapy and prognosis in primary breast cancer patients...
  38. ncbi Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients
    Takeshi Tominaga
    Breast Cancer Center, Toyosu Hospital, Showa University School of Medicine, Koto ku, Tokyo, Japan
    Clin Breast Cancer 3:55-64. 2002
    ..Further investigations on prognostic and predictive implications of TP activity in a clinical setting are warranted...
  39. ncbi Clinical features of surgical resection for pulmonary metastasis from breast cancer
    F Chen
    Department of Thoracic Surgery, Kyoto University, Kyoto, Japan
    Eur J Surg Oncol 35:393-7. 2009
    ..To confirm the role of resection of pulmonary metastases from breast cancer and to identify possible prognostic factors, we reviewed our institutional experience...
  40. ncbi Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer
    K Kuroi
    c/o Komagome Hospital, Honkomagome, Bunkyo-ku, Tokyo, Japan
    Biomed Pharmacother 59:S387-92. 2005
    ....
  41. ncbi Overexpression of MDM2 in MCF-7 promotes both growth advantage and p53 accumulation in response to estradiol
    S Saji
    2nd Department of Surgery, Gifu University School of Medicine
    Jpn J Cancer Res 90:210-8. 1999
    ..These results suggest that MDM2 may regulate the expression of p53 in the steady state and in response to E2 in breast cancer cells, and imply a novel and important role of MDM2 during breast carcinogenesis...
  42. ncbi Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer
    Shigehira Saji
    Department of Clinical Trials and Research, Breast Surgery, Tokyo Metropolitan Komagome Hospital, Honkomagome, Tokyo, Japan
    Oncogene 24:4531-9. 2005
    ..05, respectively). HDAC6 expression was an independent prognostic indicator by multivariate analysis (odds ratio = 2.82, P = 0.047). These results indicate the biological significance of HDAC6 regulation via estrogen signaling...
  43. ncbi The association between vascular endothelial growth factor-C, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer: a study with 193 cases
    Hiroko Bando
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo Metropolitan Cancer and Infectious Disease Center, Tokyo 113 8677, Japan
    Oncol Rep 15:653-9. 2006
    ..The intratumoral VEGF-C level is a significant prognostic indicator of primary breast cancer. An investigation of the mechanisms of VEGF-C protein processing in human cancer tissue should be carried out in the future...
  44. ncbi Clinical impact of assay of estrogen receptor beta cx in breast cancer
    Shigehira Saji
    Department of Surgery, Breast Oncology Unit, Tokyo Metropolitan Komagome Hospital, 3 18 22 Honkomagome, Bunkyo ku, Tokyo 113 8677, Japan
    Breast Cancer 9:303-7. 2002
    ..We conclude that, in order to better characterize breast cancers and design appropriate therapy for individual patients, assays for ER beta cx must be made available to clinicians...
  45. ncbi A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer
    Masahiro Takada
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo 113-8677, Japan
    Int J Oncol 25:397-405. 2004
    ..These findings suggest that the alteration in growth kinetics revealed by CK18NE and MIB-1 might be a surrogate marker for predicting the survival benefit from chemotherapy in primary breast cancer...
  46. ncbi [Trastuzumab treatment for breast cancer]
    Hiroyasu Yamashiro
    Department of Surgery, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital
    Nippon Rinsho 62:1305-11. 2004
    ..The optimal duration and period of trastuzumab treatment are still unknown and result of large scale randomized trial will be expected...
  47. ncbi Novel sensitizing agents: potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer
    Shigehira Saji
    Department of Surgery and Breast Oncology, Tokyo Metropolitan Komagome Hospital, 3 18 22 Honkomagome, Bunkyo ku, Tokyo 113 8677, Japan
    Breast Cancer 11:129-33. 2004
    ....
  48. ncbi Who benefits from hormone therapy?
    Masakazu Toi
    Department of Clinical Trial and Research, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan
    Breast Cancer 13:117-22. 2006
    ..Through reviewing recent outcomes of clinical trials, these issues are summarized and discussed in this review...
  49. ncbi Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer
    Shigehira Saji
    Department of Surgery and Breast Oncology, Division of Clinical Trials and Research, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
    Oncology 72:330-7. 2007
    ....
  50. ncbi Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan
    Morihiko Kimura
    Department of Surgery, Gunma Prefectural Cancer Center, Ota, Japan
    Breast Cancer 17:190-8. 2010
    ..To compare the cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy and the anthracycline-containing regimen cyclophosphamide, epirubicin, and fluorouracil (CEF) to evaluate the efficacy and safety of the latter...
  51. ncbi Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor
    Shigehira Saji
    Department of Surgery, Breast Oncology Unit, Tokyo Metropolitan Komagome Hospital, 113 8677 Tokyo, Japan
    Cancer Res 62:4849-53. 2002
    ..This is the first evidence that evaluation of ER(beta)cx along with PR may contribute to a better characterization of ER(alpha)-positive breast cancers...
  52. ncbi Weekly schedule of docetaxel in breast cancer: evaluation of response and toxicity
    Katsumasa Kuroi
    Department of Surgery, Toyosu Hospital Showa University, 4 1 18 Toyosu, Koutou ku, Tokyo 135 8577, Japan
    Breast Cancer 10:10-4. 2003
    ..However, there is still much to learn about the role of weekly docetaxel in adjuvant and neoadjuvant therapy...
  53. ncbi Anti-angiogenic therapy in breast cancer
    Mohammad Atiqur Rahman
    Breast Cancer Research Program, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan
    Biomed Pharmacother 57:463-70. 2003
    ..This article reviews the background and implementation of the current use of angiogenesis inhibitors and discusses the likely therapeutic roles in the early and advanced breast cancer together with its potential for chemoprevention...
  54. ncbi Dipalmitoylation of radicicol results in improved efficacy against tumor growth and angiogenesis in vivo
    Tsutomu Oikawa
    Medical Research and Development Center, The Tokyo Metropolitan Institute of Medical Science, Bunkyo ku, Tokyo 113 8613, Japan
    Cancer Sci 98:219-25. 2007
    ..These data suggest that 14,16-dipalmitoyl-radicicol is a promising antitumor agent with antiangiogenic activity...
  55. ncbi Metalloproteinases and tissue inhibitors of metalloproteinases
    M Toi
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Japan
    Breast Cancer Res Treat 52:113-24. 1998
    ....
  56. ncbi A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients
    Eiji Suzuki
    Breast Group, Komagome Hospital, Tokyo Metropolitan Cancer and Infectious Diseases Center, Tokyo, Japan
    Clin Cancer Res 13:1875-82. 2007
    ....
  57. ncbi Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis
    Tatsuro Yamaguchi
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo Metropolitan Cancer and Infectious Disease Center, Tokyo 113 8677, Japan
    Cancer Sci 98:405-10. 2007
    ..Furthermore, sVEGFR1 levels showed a significant prognostic value. Further studies concerning the biologic and therapeutic significance of sVEGFR1 in colorectal cancer are warranted...
  58. ncbi [VEGF (vascular endothelial growth factor)]
    Hiroko Bando
    Department of Surgery, Tokyo Metropolitan Komagome Hospital
    Nippon Rinsho 63:99-102. 2005
  59. ncbi Update of evidence in chemotherapy for breast cancer
    Hiroyasu Yamashiro
    Department of Surgery and Oncology, Kyoto University, Kyoto, 606 8507, Japan
    Int J Clin Oncol 13:3-7. 2008
    ....
  60. ncbi Oestrogen receptor-beta1 but not oestrogen receptor-betacx is of prognostic value in apocrine carcinoma of the breast
    Naoko Honma
    Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
    APMIS 116:923-30. 2008
    ..ER-beta1 itself, independent of ER-alpha expression and tamoxifen treatment, seems to have a tumor-suppressive effect, at least in apocrine carcinomas. Further study of ER-beta1 is desired to optimize breast cancer treatment...
  61. ncbi Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231
    Hiroko Bando
    Breast Cancer Research Group, Tokyo Metropolitan Cancer and Infectious Diseases Center, Honkomagome, 3-18-22, Bunkyo-ku, Tokyo 113-0087, Japan
    Biomed Pharmacother 57:333-40. 2003
    ..These commonly upregulated genes between hormone-dependent and hormone-independent cells would be a clue to study hypoxia-related events and to explore the novel therapeutic targets in human breast cancer...
  62. ncbi Impact of vasculogenesis on solid tumor growth in a rat model
    Mariko Muta
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo 113-8677, Japan
    Oncol Rep 10:1213-8. 2003
    ..Thus, our results suggest the importance of neovascularization by bone marrow-derived endothelial cells for the promotion of tumor growth...
  63. ncbi Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo
    Gaku Matsumoto
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
    Clin Cancer Res 11:1287-93. 2005
    ..Thus, DHMEQ might be a potent drug for the treatment of various breast carcinomas by inhibiting the NF-kappaB activity...
  64. ncbi Mechanical analysis of tumor growth regression by the cyclooxygenase-2 inhibitor, DFU, in a Walker256 rat tumor model: importance of monocyte chemoattractant protein-1 modulation
    Mariko Muta
    Department of Surgery, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan
    Clin Cancer Res 12:264-72. 2006
    ..In conclusion, COX-2 inhibitor DFU exerts tumor regression activity in a Walker256 tumor model by suppressing MCP-1 production in tumor tissues and in the circulation...
  65. ncbi Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer
    M Kanai
    Outpatient Oncology Unit, Kyoto University Hospital, 54 Shogin Kawahara cho, Sakyo ku, Kyoto, Japan
    Br J Cancer 105:1693-6. 2011
    ..A blood pressure drop after bevacizumab administration and its clinical significance have not been previously reported...
  66. ncbi Increase in the circulating level of hepatocyte growth factor in gastric cancer patients
    T Taniguchi
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Bunkyo ku, Japan
    Br J Cancer 75:673-7. 1997
    ..Furthermore, serum HGF levels may be of value as a tumour marker in patients with gastric cancer...
  67. ncbi Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo
    Md Zahidunnabi Dewan
    Department of Molecular Virology, Graduate School, Tokyo Medical and Dental University, 1 5 45 Yushima, Tokyo, Japan
    Breast Cancer Res Treat 104:267-75. 2007
    ..Our results suggest that NK cells play an important role in cancer growth and metastasis and could be a promising immunotherapeutic strategy against cancer either alone or in combination with conventional therapy...
  68. ncbi Protracted administration of weekly docetaxel in metastatic breast cancer
    Katsumasa Kuroi
    Department of Surgery, Showa University Toyosu Hospital, Tokyo 135 8577, Japan
    Oncol Rep 10:1479-84. 2003
    ..Thus, a weekly schedule of docetaxel at low dose maintains activity and is less myelosuppressive, however, one should be careful about cumulative toxicities...
  69. ncbi Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo
    Masakazu Toi
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
    Angiogenesis 6:121-8. 2003
    ....
  70. ncbi Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer
    Gaku Matsumoto
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo 113-8677, Japan
    Oncol Rep 10:1201-6. 2003
    ..Thus, the combination of KRN7000 and TNP470 showed a high effectiveness for the treatment of liver metastases of pancreatic cancer...
  71. ncbi Study of cancer gene therapy using IL-12-secreting endothelial progenitor cells in a rat solid tumor model
    Mariko Muta
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo 113-8677, Japan
    Oncol Rep 10:1765-9. 2003
    ..Nevertheless, our results suggest that gene-transfected EPCs could be useful as a tumor-specific drug delivery system, especially if the tumor vasculature-promoting effect of EPCs can be blocked...
  72. ncbi Dynamism of tumour vasculature in the early phase of cancer progression: outcomes from oesophageal cancer research
    Youichi Kumagai
    Department of Surgery, Tokyo Metropolitan Komagome Hospital Honkomagome, 3-18-22, Bunkyo-ku, Tokyo, Japan
    Lancet Oncol 3:604-10. 2002
    ..Such considerations will be useful not only for understanding vascular biology but also for exploring novel diagnostic, therapeutic, and preventive approaches targeting early stage or latent phase human cancer...
  73. ncbi Impact of selective Glisson transection on survival of hepatocellular carcinoma
    Koji Tsuruta
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, First Department of Surgery, Tokyo Medical and Dental University, Tokyo, Japan
    Hepatogastroenterology 49:1607-10. 2002
    ....
  74. ncbi [Neoadjuvant Chemotherapy in breast cancer]
    Eiji Suzuki
    Department of Surgery, Tokyo Metropolitan Komagome Hospital
    Nippon Rinsho 64:536-9. 2006
    ..Since pathological complete response is thought to be main factor to achieve long-term survival, development of new agent or novel combination treatment is needed...
  75. ncbi Effect of low-dose Paclitaxel and docetaxel on endothelial progenitor cells
    Mariko Muta
    Department of Health and Dietetics, Faculty of Medical Health, Teikyo Heisei University, Tokyo, Japan
    Oncology 77:182-91. 2009
    ..We aimed to clarify the cytotoxic and inhibitory effects of these drugs on EPC...
  76. ncbi Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population
    Masakazu Toi
    Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Cancer 116:3112-8. 2010
    ..The 21-gene signature has been intensively studied and incorporated into major guidelines for treatment decision in early breast cancer. However, it remains to be examined whether this system is applicable to Asian populations...
  77. ncbi Somatic mutations of LKB1 and beta-catenin genes in gastrointestinal polyps from patients with Peutz-Jeghers syndrome
    M Miyaki
    Hereditary Tumor Research Project, Tokyo Metropolitan Komagome Hospital, Japan
    Cancer Res 60:6311-3. 2000
    ....
  78. ncbi N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers
    Kyoko Hiramatsu
    Medical Research and Development Center, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
    Clin Cancer Res 11:2986-90. 2005
    ..CONCLUSION: The observations indicate that urinary DiAcSpm is a more sensitive marker than CEA, CA19-9, and CA15-3 and that it can efficiently detect colorectal and breast cancers at early stages...
  79. ncbi Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-kappaB inhibitor
    Gaku Matsumoto
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Bunkyo-ku, Tokyo 113-8677, Japan
    Int J Oncol 27:1247-55. 2005
    ..Once caspase-independent apoptosis was induced, the apoptosis demonstrated powerful cytotoxicity. Therefore, DHMEQ in combination with TNF-alpha may be a promising treatment for pancreatic cancer...
  80. ncbi Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma
    Hisashi Saji
    Breast Oncology, Tokyo Metropolitan Komagome Hospital, 3 18 22, Honkomagome, Bunkyo ku, 113 8677, Tokyo, Japan
    Cancer Lett 190:191-7. 2003
    ..This series did not demonstrate P-glycoprotein and nuclear YB-1 expression might be one of the useful prognostic marker of breast cancer...
  81. ncbi HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma
    Shin Ichiro Horiguchi
    Department of Human Pathology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan
    J Med Dent Sci 57:155-63. 2010
    ..Although the result is preliminary, it warrants further study on the role of the cytoplasmic variant form of HER2 in breast cancer growth, particularly in the aspect of neuroendocrine differentiation...
  82. ncbi DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice
    Gaku Matsumoto
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Honkomagome, Bunkyo ku, Tokyo 113 8677, Japan
    Oncol Rep 12:281-5. 2004
    ..DFU treatment also resulted in the inhibition of angiogenesis, as well as decreased COX-2 expression. Results of this study suggest that inhibitory effects of DFU might be COX-2 dependent...
  83. ncbi [Current indications for mastectomy in patients with breast cancer]
    Chikashi Nakanishi
    Department of Surgery, Breast Oncology Unit, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
    Nippon Geka Gakkai Zasshi 103:821-4. 2002
    ..In dealing with the changes in the treatment algorithm, we need to select the appropriate surgical options flexibly...
  84. ncbi Early breast cancer
    Tomoyoshi Suzuki
    Department of Surgery, Tokyo Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Tokyo 113-0025, Japan
    Int J Clin Oncol 11:108-19. 2006
    ..Another approach to keeping the disease under control is the elucidation of breast cancer's molecular biological features. Assessment of potential molecular targets can lead to early diagnosis and molecular targeted treatment...
  85. ncbi Clinical significance of estrogen receptor beta in breast cancer
    Shigehira Saji
    Department of Surgery and Breast Oncology, Tokyo Metropolitan Komagome Hospital, 3 18 22 Honkomagome, Bunkyo ku, 113 8677, Tokyo, Japan
    Cancer Chemother Pharmacol 56:21-6. 2005
    ..A selective estrogen receptor modulator, which works as an antagonist of ERalpha and an agonist of ERbeta, may be a promising chemo-preventive treatment...
  86. ncbi Novel targeting therapy concept for breast cancer treatment
    Masakazu Toi
    Nippon Yakurigaku Zasshi 132:177-9. 2008
  87. ncbi Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan
    Nahomi Tokudome
    Division of Medical Oncology, The Cancer Institute Ariake Hospital of Japanese Foundation for Cancer Research, 3 10 6 Ariake, Koto ku, Tokyo 135 8550, Japan
    Anticancer Drugs 19:753-9. 2008
    ..This combination therapy produced high response rates and good tolerability, indicating a promising role in first-line chemotherapy for HER2-overexpressing metastatic breast cancer in Japan...
  88. ncbi [Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents]
    Toru Watanabe
    Division of Internal Medicine, National Cancer Center Hospital
    Gan To Kagaku Ryoho 29:1211-21. 2002
    ..The reproducibility of the results of the two foreign studies was verified in Japanese patients, and it is concluded that the foreign trial data on exemestane can be extrapolated to Japanese...
  89. ncbi [Efficacy of biweekly paclitaxel therapy in advanced or recurrent breast cancer]
    Katsumasa Kuroi
    Dept. of Surgery, Tokyo Metropolitan Komagome Hospital
    Gan To Kagaku Ryoho 29:55-60. 2002
    ..A biweekly schedule of paclitaxel seems to be feasible and effective in patients with advanced or recurrent breast cancer...
  90. ncbi Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma
    Atsuko Kanzaki
    Department of Pathology, Institute of Development, Aging and Cancer, Tohoku University, Aoba ku, Sendai 980 8575, Japan
    Jpn J Cancer Res 93:70-7. 2002
    ..These findings suggested that ATP7B gene expression might be a chemoresistance marker for cisplatin in patients with poorly differentiated breast carcinoma...
  91. ncbi [A case of primary breast cancer who responded remarkably to the neoadjuvant chemotherapy with the combination of docetaxel and cyclophosphamide]
    Hiroshi Yoshibayashi
    Dept of Surgery Breast Surgery, Kyoto University Hospital
    Gan To Kagaku Ryoho 35:987-90. 2008
    ..We concluded that the combination of docetaxel and cyclophosphamide was a good option for neoadjuvant chemotherapy for early breast cancer...
  92. ncbi Expression of uridine and thymidine phosphorylase genes in human breast carcinoma
    Atsuko Kanzaki
    Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
    Int J Cancer 97:631-5. 2002
    ..Our findings suggest that the expression level of UPase gene may be an independent prognostic marker in human breast carcinoma...
  93. ncbi Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer
    Louis Wing Cheong Chow
    Department of Surgery, University of Hong Kong Medical Centre, Pokfulam, Hong Kong
    J Steroid Biochem Mol Biol 111:13-7. 2008
    ..To evaluate the efficacy and safety of combing aromatase inhibitor (AI) and cyclooxygenase-2 (COX-2) inhibitor neoadjuvantly in postmenopausal patients with invasive hormone-sensitive breast cancer...
  94. ncbi Expression of thymidylate synthase and thymidine phosphorylase in human breast carcinoma: implication for method to detect expression of these molecules in clinic
    Osamu Ogura
    Ogura Memorial Hospital, Kotobukichou 8-21-2, Kagoshima 893, Japan
    Cancer Lett 190:97-104. 2003
    ..These imply that immunohistochemical analysis of dThdPase and TS is available for selection of patients who will be received 5-FU based chemotherapy...
  95. ncbi Angiogenic inhibitors: a new therapeutic strategy in oncology
    Giampietro Gasparini
    Division of Medical Oncology, San Filippo Neri Hospital, Via G Martinotti, 20 00135 Rome, Italy
    Nat Clin Pract Oncol 2:562-77. 2005
    ....
  96. ncbi Quantification of vascular endothelial growth factor-C (VEGF-C) by a novel ELISA
    Herbert A Weich
    Department of Gene Regulation and Differentiation National Research Centre for Biotechnology GBF, Mascheroder Weg 1, 38124 Braunschweig, Germany
    J Immunol Methods 285:145-55. 2004
    ..This ELISA will be a useful tool for investigations concerning the physiological function of VEGF-C in lymphangiogenesis under normal and pathophysiological conditions...
  97. ncbi Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma
    Masamichi Yasuno
    Department of Surgical Oncology, Tokyo Medical and Dental University, 1 5 45 Yushima Bunkyou ku, Tokyo 113 8519, Japan
    Oncol Rep 13:405-12. 2005
    ..0222). TP produced by tumor cells has a stimulatory effect on tumor angiogenesis, while that produced by stromal cells plays an entirely different role. The latter may enhance the anticancer effect of 5-FU via its catalyzed function...
  98. ncbi 1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial
    Takeshi Tominaga
    Breast Cancer Center, Toyosu Hospital, Showa University School of Medicine, Tokyo 135 8577, Japan
    Oncol Rep 12:797-803. 2004
    ..Study results suggest that 2-year HCT therapy including the oral 5-FU anti-cancer drug HCFU is a useful adjuvant therapy which can replace CMFT therapy in early breast cancer cases with 3 or lower metastatic lymph nodes...
  99. ncbi Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues
    Hiroko Bando
    Department of Gene Regulation and Differentiation, National Research Centre for Biotechnology (GBF, Braunschweig, Germany
    Int J Cancer 111:184-91. 2004
    ..This assay provides a useful tool for the investigations of the expression levels of VEGFR-3 in physiological and pathological processes, particular in cancer and in lymphangiogenesis-related disease...
  100. ncbi Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer
    Katsumasa Kuroi
    Japan Breast Cancer Research Group, Cancer Institute
    Breast Cancer 13:38-48. 2006
    ..CONCLUSION: Assessment of pCR needs to be standardized, with verification for reliability and validity. For now, the non-equivalency in the definition of pCR should be taken into account when comparing the results of PST...
  101. ncbi A pilot phase II study of capecitabine in advanced or recurrent breast cancer
    Toshiaki Saeki
    Department of Clinical Research and Surgery, National Hospital Organization Shikoku Cancer Center
    Breast Cancer 13:49-57. 2006
    ..The Japanese regimen is worthy of further study in larger numbers of patients in phase II / III clinical trials...